PMID- 35968352
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220816
IS  - 2156-6976 (Print)
IS  - 2156-6976 (Electronic)
IS  - 2156-6976 (Linking)
VI  - 12
IP  - 7
DP  - 2022
TI  - Different interventional time of hepatic arterial infusion with PD-1 inhibitor 
      for advanced biliary tract cancer: a multicenter retrospective study.
PG  - 3455-3463
AB  - This study investigated the efficacy and safety of hepatic artery infusion 
      chemotherapy (HAIC) combined with PD-1 immunotherapy for advanced biliary tract 
      cancer (BTC) and evaluated the optimal timing of HAIC. A total of 36 unresectable 
      BTC patients treated with HAIC and PD-1 inhibitors between September 2019 and 
      July 2021 were included in this study. Overall survival (OS), progression-free 
      survival (PFS), tumor response, and adverse events (AEs) were investigated. 
      Overall, 52.8% patients with advanced BTC were in stage IV, 23 patients who 
      progressed after receiving PD-1 inhibitor had undergone HAIC, and 23 patients 
      have received 2 or more lines of therapy. The median OS was 8.8 months (range: 
      4.0-24.0 months), and the median PFS was 3.7 months. The objective response rate 
      and disease control rate were 11.5% and 76.9%, respectively. In the subgroup 
      analysis, patients who treated with HAIC early without progression after 
      immunotherapy were associated with a trend toward better OS (median 13.0 vs. 7.6 
      months; P = 0.004) and PFS (median 7.9 vs. 3.6 months; P = 0.09) compared to with 
      HAIC with progression after PD-1 treatment. No treatment-related deaths occurred. 
      A total of 44.4% of the patients experienced grade 3 or 4 AEs. We conclude that 
      the combination of HAIC and PD-1 inhibitors is safe and effective. Early HAIC 
      combined with immunotherapy can effectively prolong the overall survival of 
      patients with advanced BTC.
CI  - AJCR Copyright (c) 2022.
FAU - Zhang, Ting
AU  - Zhang T
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing, 
      China.
FAU - Yang, Xu
AU  - Yang X
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing, 
      China.
FAU - Yang, Xiaobo
AU  - Yang X
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing, 
      China.
FAU - Zheng, Kanglian
AU  - Zheng K
AD  - Department of Interventional Oncology, Key Laboratory of Carcinogenesis and 
      Translational Research (Ministry of Education), Peking University Cancer Hospital 
      & Institute Beijing, China.
FAU - Wang, Yanyu
AU  - Wang Y
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing, 
      China.
FAU - Wang, Yunchao
AU  - Wang Y
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing, 
      China.
FAU - Sang, Xinting
AU  - Sang X
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing, 
      China.
FAU - Lu, Xin
AU  - Lu X
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing, 
      China.
FAU - Xu, Yiyao
AU  - Xu Y
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing, 
      China.
FAU - Wang, Xiaodong
AU  - Wang X
AD  - Department of Interventional Oncology, Key Laboratory of Carcinogenesis and 
      Translational Research (Ministry of Education), Peking University Cancer Hospital 
      & Institute Beijing, China.
FAU - Zhao, Haitao
AU  - Zhao H
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20220715
PL  - United States
TA  - Am J Cancer Res
JT  - American journal of cancer research
JID - 101549944
PMC - PMC9360239
OTO - NOTNLM
OT  - Biliary tract cancer
OT  - PD-1 inhibitor
OT  - combination therapy
OT  - hepatic arterial infusion chemotherapy
OT  - interventional time of HAIC
COIS- None.
EDAT- 2022/08/16 06:00
MHDA- 2022/08/16 06:01
PMCR- 2022/07/15
CRDT- 2022/08/15 04:13
PHST- 2022/02/21 00:00 [received]
PHST- 2022/06/26 00:00 [accepted]
PHST- 2022/08/15 04:13 [entrez]
PHST- 2022/08/16 06:00 [pubmed]
PHST- 2022/08/16 06:01 [medline]
PHST- 2022/07/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Cancer Res. 2022 Jul 15;12(7):3455-3463. eCollection 2022.